16 September 2026 editorial review · Trial
GLP-1 receptor agonist for stage-1 T1D: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Baseline trial evidence review: A–H
Outcome: Expanded sparse summary/eligibility using current registry design, inclusion criteria and primary outcome; no efficacy inferred from registration.
Registry: NCT07430332. Registered endpoint checked: C-peptide area under the curve (12 months); C-peptide area under the curve (AUC) (12 months). Eligibility check: Registry age 12 Years to 70 Years; substantive diagnosis/stage, device and other inclusion restrictions were compared with the public eligibility summary. The registry remains the source for full exclusions. Limits: No usable primary abstract was independently recovered in this pass for this record. Protocol/design wording was assessed; any existing detailed sponsor, conference or historical outcome claims require their cited source and were not independently certified through full-text review.